Mechanistic evaluation of a novel cyclohexenone derivative’s functionality against nociception and inflammation: An in-vitro, in-vivo and in-silico approach

The synthesis of a novel cyclohexanone derivative (CHD; Ethyl 6-(4-metohxyphenyl)-2-oxo-4-phenylcyclohexe-3-enecarboxylate) was described and the subsequent aim to perform an in vitro , vivo silico pharmacological evaluation as putative anti-nociceptive anti-inflammatory agent mice. Initial studies revealed that CHD inhibited both cyclooxygenase-2 (COX-2) 5-lipoxygenase (5-LOX) enzymes it also reduced mRNA expression COX-2 pro-inflammatory cytokines TNF-? IL-1?. It then shown dose dependently chemically induced tonic nociception abdominal constriction assay phasic thermal (i.e. anti-nociception) hot plate tail immersion tests comparison with aspirin tramadol respectively. test outcomes indicated possible moderate centrally mediated anti-nociception which, case test, pentylenetetrazole (PTZ) naloxone reversible, implicating GABAergic opioidergic mechanisms. effective against neurogenic inflammatory mediator phases formalin disclosed activity phlogistic agents, carrageenan, serotonin, histamine xylene compared standard drugs edema volume tests. In possessed preferential affinity for GABA A opioid target sites this supported by molecular dynamic simulations where computation free energy binding favored formation stable complexes these sites. These findings suggest has prospective properties, probably through interactions supplemented 5-LOX enzyme inhibition addition reducing cytokine expression. may therefore possess potentially beneficial therapeutic effectiveness management inflammation pain. • synthesized (CHD) tested . plus COX-2, IL-1? produced inhibitory nociceptive had